Double‐blind, randomized, placebo‐controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of <scp>TAK</scp>‐683, an investigational metastin analogue in healthy men

Abstract

In healthy men, s.c. administration of TAK-683 was well tolerated at all dose levels. The PK profile of TAK-683 was favourable, and TAK-683 suppressed testosterone profoundly during continuous dosing. Further investigation of metastin analogues is warranted for the treatment of castration-resistant prostate cancer.